<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37315370</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications.</ArticleTitle><Pagination><StartPage>110439</StartPage><MedlinePgn>110439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2023.110439</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(23)00762-2</ELocationID><Abstract><AbstractText>COVID-19-infected individuals and those who recovered from the infection have been demonstrated to have elevated liver enzymes or abnormal liver biochemistries, particularly with preexisting liver diseases, liver metabolic disorders, viral hepatitis, and other hepatic comorbidities. However, possible crosstalk and intricate interplay between COVID-19 and liver disease severity are still elusive, and the available data are murky and confined. Similarly, the syndemic of other blood-borne infectious diseases, chemical-induced liver injuries, and chronic hepatic diseases continued to take lives while showing signs of worsening due to the COVID-19 crisis. Moreover, the pandemic is not over yet and is transitioning to becoming an epidemic in recent years; hence, monitoring liver function tests (LFTs) and assessing hepatic consequences of COVID-19 in patients with or without liver illnesses would be of paramount interest. This pragmatic review explores the correlations between COVID-19 and liver disease severity based on abnormal liver biochemistries and other possible mechanisms in individuals of all ages from the emergence of the COVID-19 pandemic to the post-pandemic period. The review also alludes to clinical perspectives of such interactions to curb overlapping hepatic diseases in people who recovered from the infection or living with long COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Imam</LastName><ForeName>Mohammad T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almalki</LastName><ForeName>Ziyad S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al Kharj 11942, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alzahrani</LastName><ForeName>Abdullah R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ghamdi</LastName><ForeName>Saeed S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falemban</LastName><ForeName>Alaa H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alanazi</LastName><ForeName>Ibrahim M</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahzad</LastName><ForeName>Naiyer</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad Alrooqi</LastName><ForeName>Munira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, Umm Al-Qura University, Makkah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jabeen</LastName><ForeName>Qaiser</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahid</LastName><ForeName>Imran</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Al-Abidiyah, Makkah 21955, Saudi Arabia. Electronic address: iyshahid@uqu.edu.sa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008107" MajorTopicYN="Y">Liver Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute liver disease</Keyword><Keyword MajorTopicYN="N">Chronic liver disease</Keyword><Keyword MajorTopicYN="N">Coronavirus infectious disease-19</Keyword><Keyword MajorTopicYN="N">Hepatic injury</Keyword><Keyword MajorTopicYN="N">Liver function test</Keyword><Keyword MajorTopicYN="N">Viral hepatitis</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37315370</ArticleId><ArticleId IdType="pmc">PMC10247890</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2023.110439</ArticleId><ArticleId IdType="pii">S1567-5769(23)00762-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang C., Shi L., Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020;5(5):428&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7129165</ArticleId><ArticleId IdType="pubmed">32145190</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W., Barnaby D.P., Becker L.B., Chelico J.D., Cohen S.L., Cookingham J., Coppa K., Diefenbach M.A., Dominello A.J., Duer-Hefele J., Falzon L., Gitlin J., Hajizadeh N., Harvin T.G., Hirschwerk D.A., Kim E.J., Kozel Z.M., Marrast L.M., Mogavero J.N., Osorio G.A., Qiu M., Zanos T.P. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeckmans J., Rodrigues R.M., Demuyser T., Pi&#xe9;rard D., Vanhaecke T., Rogiers V. COVID-19 and drug-induced liver injury: a problem of plenty or a petty point? Arch. Toxicol. 2020;94(4):1367&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138655</ArticleId><ArticleId IdType="pubmed">32266419</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Webb G.J., Barritt A.S.T., Moon A.M., Stamataki Z., Wong V.W., Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives, Nature reviews. Gastroenterol. Hepatol. 2021;18(5):348&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7945972</ArticleId><ArticleId IdType="pubmed">33692570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushner T., Cafardi J. Chronic Liver Disease and COVID-19: Alcohol use disorder/alcohol-associated liver disease, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, autoimmune liver disease, and compensated cirrhosis. Clin. Liver Dis. 2020;15(5):195&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280613</ArticleId><ArticleId IdType="pubmed">32537135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalbafan M., Khademoreza N. What we can learn from COVID-19 outbreak in Iran about the importance of alcohol use education. Am. J. Drug Alcohol Abuse. 2020;46(3):385&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">32310677</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M.Z., Ahmed O., Aibao Z., Hanbin S., Siyu L., Ahmad A. Epidemic of COVID-19 in China and associated psychological problems. Asian J. Psychiatr. 2020;51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194662</ArticleId><ArticleId IdType="pubmed">32315963</ArticleId></ArticleIdList></Reference><Reference><Citation>Da B.L., Im G.Y., Schiano T.D. Coronavirus disease 2019 hangover: A rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology (Baltimore Md.) 2020;72(3):1102&#x2013;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">32369624</ArticleId></ArticleIdList></Reference><Reference><Citation>Fix O.K., Hameed B., Fontana R.J., Kwok R.M., McGuire B.M., Mulligan D.C., Pratt D.S., Russo M.W., Schilsky M.L., Verna E.C., Loomba R., Cohen D.E., Bezerra J.A., Reddy K.R., Chung R.T. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Hepatology (Baltimore, Md.) 2020;72(1):287&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262242</ArticleId><ArticleId IdType="pubmed">32298473</ArticleId></ArticleIdList></Reference><Reference><Citation>Day M. Covid-19: European drugs agency to review safety of ibuprofen. BMJ (Clinical research ed.) 2020;368</Citation><ArticleIdList><ArticleId IdType="pubmed">32205306</ArticleId></ArticleIdList></Reference><Reference><Citation>Torjesen I. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear. BMJ (Clinical research ed.) 2020;369</Citation><ArticleIdList><ArticleId IdType="pubmed">32303505</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow K.W., Pham N.V., Ibrahim B.M., Hong K., Saab S. Autoimmune hepatitis-like syndrome following COVID-19 vaccination: A systematic review of the literature. Dig. Dis. Sci. 2022;67(9):4574&#x2013;4580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9052185</ArticleId><ArticleId IdType="pubmed">35486203</ArticleId></ArticleIdList></Reference><Reference><Citation>Portincasa P., Krawczyk M., Machill A., Lammert F., Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur. J. Intern. Med. 2020;77:18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262543</ArticleId><ArticleId IdType="pubmed">32507608</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrsaljko N., Samadan L., Viskovic K., Mehmedovi&#x107; A., Budimir J., Vince A., Papic N. Association of nonalcoholic fatty liver disease with COVID-19 severity and pulmonary thrombosis: CovidFAT, a prospective, observational cohort study. Open Forum Infect. Dis. 2022;9(4):ofac073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903409</ArticleId><ArticleId IdType="pubmed">35287335</ArticleId></ArticleIdList></Reference><Reference><Citation>Riazi K., Azhari H., Charette J.H., Underwood F.E., King J.A., Afshar E.E., Swain M.G., Congly S.E., Kaplan G.G., Shaheen A.A. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2022;7(9):851&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">35798021</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip T.C., Gill M., Wong G.L., Liu K. Management of hepatitis B virus reactivation due to treatment of COVID-19. Hep. Intl. 2022;16(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889512</ArticleId><ArticleId IdType="pubmed">35235148</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.A., Franco S. Impact of COVID-19 in liver disease progression. Hepatology Commun. 2021;5(7):1138&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8239862</ArticleId><ArticleId IdType="pubmed">34533001</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liu J., Lu M., Yang D., Zheng X. Liver injury during highly pathogenic human coronavirus infections, Liver international: official journal of the International Association for the Study of the. Liver. 2020;40(5):998&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228361</ArticleId><ArticleId IdType="pubmed">32170806</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Z.P., Mei X., Zhang Y.Y., Zou Y., Zhang Z.G., Zhu H., Guo H.Y., Liu Y., Ling Y., Zhang X.Y., Wang J.F., Lu H.Z. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin. J. Hepatol. 2020;28(3):229&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">32270660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji D., Qin E., Xu J., Zhang D., Cheng G., Wang Y., Lau G. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J. Hepatol. 2020;73(2):451&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7141624</ArticleId><ArticleId IdType="pubmed">32278005</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini R.K., Saini N., Ram S., Soni S.L., Suri V., Malhotra P., Kaur J., Verma I., Sharma S., Zohmangaihi D. COVID-19 associated variations in liver function parameters: a retrospective study. Postgrad. Med. J. 2022;98(1156):91&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">33184141</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenough T.C., Carville A., Coderre J., Somasundaran M., Sullivan J.L., Luzuriaga K., Mansfield K. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am. J. Pathol. 2005;167(2):455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1603565</ArticleId><ArticleId IdType="pubmed">16049331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am. J. Emerg. Med. 2008;26(6):711&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">18606328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahu K.K., Cerny J. A review on how to do hematology consults during COVID-19 pandemic. Blood Rev. 2021;47</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648889</ArticleId><ArticleId IdType="pubmed">33199084</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., Du B., Li L.J., Zeng G., Yuen K.Y., Chen R.C., Tang C.L., Wang T., Chen P.Y., Xiang J., Li S.Y., Wang J.L., Liang Z.J., Peng Y.X., Wei L., Liu Y., Hu Y.H., Peng P., Wang J.M., Liu J.Y., Chen Z., Li G., Zheng Z.J., Qiu S.Q., Luo J., Ye C.J., Zhu S.Y., Zhong N.S. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., Sun Y., Liu Y., He Q., Chen J., Liu L., Xu L. COVID-19: Abnormal liver function tests. J. Hepatol. 2020;73(3):566&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194951</ArticleId><ArticleId IdType="pubmed">32298767</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q., Huang D., Ou P., Yu H., Zhu Z., Xia Z., Su Y., Ma Z., Zhang Y., Li Z., He Q., Liu L., Fu Y., Chen J. COVID-19 in a designated infectious diseases hospital outside Hubei Province. China, Allergy. 2020;75(7):1742&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pubmed">32239761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom P.P., Meyerowitz E.A., Reinus Z., Daidone M., Gustafson J., Kim A.Y., Schaefer E., Chung R.T. Liver biochemistries in hospitalized patients with COVID-19. Hepatology (Baltimore Md.) 2021;73(3):890&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">32415860</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130(5):2620&#x2013;2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X.W., Wu X.X., Jiang X.G., Xu K.J., Ying L.J., Ma C.L., Li S.B., Wang H.Y., Zhang S., Gao H.N., Sheng J.F., Cai H.L., Qiu Y.Q., Li L.J. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clinical research ed.) 2020;368</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224340</ArticleId><ArticleId IdType="pubmed">32075786</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Tao Z.W., Wang L., Yuan M.L., Liu K., Zhou L., Wei S., Deng Y., Liu J., Liu H.G., Yang M., Hu Y. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020;133(9):1032&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147279</ArticleId><ArticleId IdType="pubmed">32118640</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Liu W., Liu K., Fang Y.Y., Shang J., Zhou L., Wang K., Leng F., Wei S., Chen L., Liu H.G. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin. Med. J. (Engl) 2020;133(11):1261&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289311</ArticleId><ArticleId IdType="pubmed">32209890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., Guan L., Wei Y., Li H., Wu X., Xu J., Tu S., Zhang Y., Chen H., Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Qingxian C., Huang D., Yu H., Zhu Z., Xia Z., Su Y., Li Z., Zhou G., Gou J., Qu J., Sun Y., Liu Y., He Q., Chen J., Liu L., Xu L. Characteristics of liver tests in COVID-19 patients. J. Hepatol. 2020;73(3):566&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194951</ArticleId><ArticleId IdType="pubmed">32298767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., He L., Zhang Q., Huang Z., Che X., Hou J., Wang H., Shen H., Qiu L., Li Z., Geng J., Cai J., Han H., Li X., Kang W., Weng D., Liang P., Jiang S. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J. Pathol. 2004;203(2):622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167761</ArticleId><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau T.N., Lee K.C., Yao H., Tsang T.Y., Chow T.C., Yeung Y.C., Choi K.W., Tso Y.K., Lau T., Lai S.T., Lai C.L. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology (Baltimore Md.) 2004;39(2):302&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165792</ArticleId><ArticleId IdType="pubmed">14767982</ArticleId></ArticleIdList></Reference><Reference><Citation>D.E. Gordon, G.M. Jang, M. Bouhaddou, J. Xu, K. Obernier, K.M. White, M.J. O'Meara, V.V. Rezelj, J.Z. Guo, D.L. Swaney, T.A. Tummino, R. H&#xfc;ttenhain, R.M. Kaake, A.L. Richards, B. Tutuncuoglu, H. Foussard, J. Batra, K. Haas, M. Modak, M. Kim, P. Haas, B.J. Polacco, H. Braberg, J.M. Fabius, M. Eckhardt, M. Soucheray, M.J. Bennett, M. Cakir, M.J. McGregor, Q. Li, B. Meyer, F. Roesch, T. Vallet, A. Mac Kain, L. Miorin, E. Moreno, Z.Z.C. Naing, Y. Zhou, S. Peng, Y. Shi, Z. Zhang, W. Shen, I.T. Kirby, J.E. Melnyk, J.S. Chorba, K. Lou, S.A. Dai, I. Barrio-Hernandez, D. Memon, C. Hernandez-Armenta, J. Lyu, C.J.P. Mathy, T. Perica, K.B. Pilla, S.J. Ganesan, D.J. Saltzberg, R. Rakesh, X. Liu, S.B. Rosenthal, L. Calviello, S. Venkataramanan, J. Liboy-Lugo, Y. Lin, X.P. Huang, Y. Liu, S.A. Wankowicz, M. Bohn, M. Safari, F.S. Ugur, C. Koh, N.S. Savar, Q.D. Tran, D. Shengjuler, S.J. Fletcher, M.C. O'Neal, Y. Cai, J.C.J. Chang, D.J. Broadhurst, S. Klippsten, P.P. Sharp, N.A. Wenzell, D. Kuzuoglu-Ozturk, H.Y. Wang, R. Trenker, J.M. Young, D.A. Cavero, J. Hiatt, T.L. Roth, U. Rathore, A. Subramanian, J. Noack, M. Hubert, R.M. Stroud, A.D. Frankel, O.S. Rosenberg, K.A. Verba, D.A. Agard, M. Ott, M. Emerman, N. Jura, M. von Zastrow, E. Verdin, A. Ashworth, O. Schwartz, C. d'Enfert, S. Mukherjee, M. Jacobson, H.S. Malik, D.G. Fujimori, T. Ideker, C.S. Craik, S.N. Floor, J.S. Fraser, J.D. Gross, A. Sali, B.L. Roth, D. Ruggero, J. Taunton, T. Kortemme, P. Beltrao, M. Vignuzzi, A. Garc&#xed;a-Sastre, K.M. Shokat, B.K. Shoichet, N.J. Krogan, A SARS-CoV-2 protein interaction map reveals targets for drug repurposing, Nature 583(7816) (2020) 459-468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckholz A.P., Kaplan A., Rosenblatt R.E., Wan D. Clinical characteristics, diagnosis, and outcomes of 6 patients with COVID-19 infection and rhabdomyolysis. Mayo Clin. Proc. 2020;95(11):2557&#x2013;2559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831467</ArticleId><ArticleId IdType="pubmed">33153641</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H., Wang C., Zhao J., Sun X., Tian R., Wu W., Wu D., Ma J., Chen Y., Zhang D., Xie J., Yan X., Zhou X., Liu Z., Wang J., Du B., Qin Y., Gao P., Qin X., Xu Y., Zhang W., Li T., Zhang F., Zhao Y., Li Y., Zhang S. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 2020;382(17):e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;az L.A., Idalsoaga F., Cannistra M., Candia R., Cabrera D., Barrera F., Soza A., Graham R., Riquelme A., Arrese M., Leise M.D., Arab J.P. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. World J. Gastroenterol. 2020;26(48):7693&#x2013;7706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7789052</ArticleId><ArticleId IdType="pubmed">33505145</ArticleId></ArticleIdList></Reference><Reference><Citation>Papic N., Pangercic A., Vargovic M., Barsic B., Vince A., Kuzman I. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respi. Viruses. 2012;6(3):e2&#x2013;e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941665</ArticleId><ArticleId IdType="pubmed">21951624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., Ng S.C., Ghosh S., Chen M.H. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2020;5(7):667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217643</ArticleId><ArticleId IdType="pubmed">32405603</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponziani F.R., Del Zompo F., Nesci A., Santopaolo F., Ianiro G., Pompili M., Gasbarrini A. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment. Pharmacol. Ther. 2020;52(6):1060&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361563</ArticleId><ArticleId IdType="pubmed">32628793</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip T.C., Lui G.C., Wong V.W., Chow V.C., Ho T.H., Li T.C., Tse Y.K., Hui D.S., Chan H.L., Wong G.L. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut. 2021;70(4):733&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">32641471</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S., Hellmuth J.C., Scherer C., Muenchhoff M., Mayerle J., Gerbes A.L. Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study. Gut. 2021;70(10):1925&#x2013;1932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852072</ArticleId><ArticleId IdType="pubmed">33514597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Z.Y., Li G.X., Chen L., Shu C., Song J., Wang W., Wang Y.W., Chen Q., Jin G.N., Liu T.T., Liang J.N., Zhu P., Zhu W., Li Y., Zhang B.H., Feng H., Zhang W.G., Yin Z.Y., Yu W.K., Yang Y., Zhang H.Q., Tang Z.P., Wang H., Hu J.B., Liu J.H., Yin P., Chen X.P., Zhang B. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J. Hepatol. 2021;74(6):1295&#x2013;1302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749734</ArticleId><ArticleId IdType="pubmed">33347952</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zheng L., Liu L., Zhao M., Xiao J., Zhao Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city. China, Liver Int.: official J. Int. Assoc. Study Liver. 2020;40(9):2095&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32239796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Zhu R., Bai T., Han P., He Q., Jing M., Xiong X., Zhao X., Quan R., Chen C., Zhang Y., Tao M., Yi J., Tian D., Yan W. Clinical features of patients infected with coronavirus disease 2019 With elevated liver biochemistries: A multicenter, retrospective study. Hepatology (Baltimore Md.) 2021;73(4):1509&#x2013;1520.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361581</ArticleId><ArticleId IdType="pubmed">32602604</ArticleId></ArticleIdList></Reference><Reference><Citation>Phipps M.M., Barraza L.H., LaSota E.D., Sobieszczyk M.E., Pereira M.R., Zheng E.X., Fox A.N., Zucker J., Verna E.C. Acute liver injury in COVID-19: Prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology (Baltimore Md.) 2020;72(3):807&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300739</ArticleId><ArticleId IdType="pubmed">32473607</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav D.K., Singh A., Zhang Q., Bai X., Zhang W., Yadav R.K., Singh A., Zhiwei L., Adhikari V.P., Liang T. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7948176</ArticleId><ArticleId IdType="pubmed">32669289</ArticleId></ArticleIdList></Reference><Reference><Citation>F. Lei, Y.M. Liu, F. Zhou, J.J. Qin, P. Zhang, L. Zhu, X.J. Zhang, J. Cai, L. Lin, S. Ouyang, X. Wang, C. Yang, X. Cheng, W. Liu, H. Li, J. Xie, B. Wu, H. Luo, F. Xiao, J. Chen, L. Tao, G. Cheng, Z.G. She, J. Zhou, H. Wang, J. Lin, P. Luo, S. Fu, J. Zhou, P. Ye, B. Xiao, W. Mao, L. Liu, Y. Yan, L. Liu, G. Chen, H. Li, X. Huang, B.H. Zhang, Y. Yuan, Longitudinal association between markers of liver injury and mortality in COVID-19 in China, Hepatology (Baltimore, Md.) 72(2) (2020) 389-398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267515</ArticleId><ArticleId IdType="pubmed">32359177</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangash M.N., Patel J.M., Parekh D., Murphy N., Brown R.M., Elsharkawy A.M., Mehta G., Armstrong M.J., Neil D. SARS-CoV-2: Is the liver merely a bystander to severe disease? J. Hepatol. 2020;73(4):995&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7265856</ArticleId><ArticleId IdType="pubmed">32502510</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Eberhardt C.S., Boettler T., Belli L.S., Berenguer M., Buti M., Jalan R., Mondelli M.U., Moreau R., Shouval D., Berg T., Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J. Hepatol. 2022;77(4):1161&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9296253</ArticleId><ArticleId IdType="pubmed">35868584</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer E.A.K., Arvind A., Bloom P.P., Chung R.T. Interrelationship between coronavirus infection and liver disease. Clin. Liver Dis. 2020;15(5):175&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242011</ArticleId><ArticleId IdType="pubmed">32489653</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Lian J.S., Hu J.H., Gao J., Zheng L., Zhang Y.M., Hao S.R., Jia H.Y., Cai H., Zhang X.L., Yu G.D., Xu K.J., Wang X.Y., Gu J.Q., Zhang S.Y., Ye C.Y., Jin C.L., Lu Y.F., Yu X., Yu X.P., Huang J.R., Xu K.L., Ni Q., Yu C.B., Zhu B., Li Y.T., Liu J., Zhao H., Zhang X., Yu L., Guo Y.Z., Su J.W., Tao J.J., Lang G.J., Wu X.X., Wu W.R., Qv T.T., Xiang D.R., Yi P., Shi D., Chen Y., Ren Y., Qiu Y.Q., Li L.J., Sheng J., Yang Y. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002&#x2013;1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7133387</ArticleId><ArticleId IdType="pubmed">32213556</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Zhong N.S. Clinical characteristics of covid-19 in China. Reply, New Engl. J. Med. 2020;382(19):1861&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220206</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q., Chen J. Reply to: &#x201c;Clinical characteristics of COVID-19 patients with abnormal liver tests&#x201d;. J. Hepatol. 2020;73(3):713&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201227</ArticleId><ArticleId IdType="pubmed">32387074</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(7):811&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I.C., Huo T.I., Huang Y.H. Gastrointestinal and liver manifestations in patients with COVID-19. J. Chinese Med. Assoc.: JCMA. 2020;83(6):521&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7176263</ArticleId><ArticleId IdType="pubmed">32243269</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D., Poucke S.V., Liu W.Y., Zheng M.H. COVID-19 and liver dysfunction: Current insights and emergent therapeutic strategies. J. Clin. Transl. Hepatol. 2020;8(1):18&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132016</ArticleId><ArticleId IdType="pubmed">32274342</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Z., Chen L., Li J., Cheng X., Yang J., Tian C., Zhang Y., Huang S., Liu Z., Cheng J. Clinical features of COVID-19-related liver functional abnormality. Clinical Gastroenterol. Hepatol.: Official Clin. Pract. J. Am. Gastroenterol. Assoc. 2020;18(7):1561&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194865</ArticleId><ArticleId IdType="pubmed">32283325</ArticleId></ArticleIdList></Reference><Reference><Citation>Redd W.D., Zhou J.C., Hathorn K.E., McCarty T.R., Bazarbashi A.N., Thompson C.C., Shen L., Chan W.W. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome coronavirus 2 infection in the United States: A multicenter cohort study. Gastroenterology. 2020;159(2):765&#x2013;767.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195377</ArticleId><ArticleId IdType="pubmed">32333911</ArticleId></ArticleIdList></Reference><Reference><Citation>Seretis C., Lagoudianakis E., Salemis N., Pappas A., Gemenetzis G., Seretis F., Gourgiotis S. Liver biochemistry during the course of influenza A/H1N1 infection. Gastroenterol. Res. 2013;6(3):103&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051153</ArticleId><ArticleId IdType="pubmed">27785237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang K.W., Ho P.L., Ooi G.C., Yee W.K., Wang T., Chan-Yeung M., Lam W.K., Seto W.H., Yam L.Y., Cheung T.M., Wong P.C., Lam B., Ip M.S., Chan J., Yuen K.Y., Lai K.N. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N. Engl. J. Med. 2003;348(20):1977&#x2013;1985.</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000;342(17):1266&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10781624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J., Han B., Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518&#x2013;1519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7130192</ArticleId><ArticleId IdType="pubmed">32142785</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 2013;11(12):836&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5147543</ArticleId><ArticleId IdType="pubmed">24217413</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., M&#xf8;ller R., Jordan T.X., Oishi K., Panis M., Sachs D., Wang T.T., Schwartz R.E., Lim J.K., Albrecht R.A., tenOever B.R. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036&#x2013;1045.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka T., Narazaki M., Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol. 2014;6(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176007</ArticleId><ArticleId IdType="pubmed">25190079</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F.S., Fan J.G., Zhang Z., Gao B., Wang H.Y. The global burden of liver disease: the major impact of China. Hepatology (Baltimore Md.) 2014;60(6):2099&#x2013;2108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4867229</ArticleId><ArticleId IdType="pubmed">25164003</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., Landt C.L., Harrison S.A. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">20858492</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011;34(3):274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">21623852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazo M., Hernaez R., Eberhardt M.S., Bonekamp S., Kamel I., Guallar E., Koteish A., Brancati F.L., Clark J.M. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988&#x2013;1994. Am. J. Epidemiol. 2013;178(1):38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3698993</ArticleId><ArticleId IdType="pubmed">23703888</ArticleId></ArticleIdList></Reference><Reference><Citation>Younossi Z.M., Stepanova M., Afendy M., Fang Y., Younossi Y., Mir H., Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol.: Official Clin. Pract. J. Am. Gastroenterol. Assoc. 2011;9(6):524&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">21440669</ArticleId></ArticleIdList></Reference><Reference><Citation>Boettler T., Newsome P.N., Mondelli M.U., Maticic M., Cordero E., Cornberg M., Berg T. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep.: Innovat. Hepatol. 2020;2(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128473</ArticleId><ArticleId IdType="pubmed">32289115</ArticleId></ArticleIdList></Reference><Reference><Citation>Paizis G., Tikellis C., Cooper M.E., Schembri J.M., Lew R.A., Smith A.I., Shaw T., Warner F.J., Zuilli A., Burrell L.M., Angus P.W. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790&#x2013;1796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1774784</ArticleId><ArticleId IdType="pubmed">16166274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng K.I., Gao F., Wang X.B., Sun Q.F., Pan K.H., Wang T.Y., Ma H.L., Chen Y.P., Liu W.Y., George J., Zheng M.H. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metab. Clin. Exp. 2020;108</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166301</ArticleId><ArticleId IdType="pubmed">32320741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnel A.R., Bunchorntavakul C., Reddy K.R. Immune dysfunction and infections in patients with cirrhosis. Clin. Gastroenterol. Hepatology: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2011;9(9):727&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pubmed">21397731</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper E.B., Asrani S.K. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J. Hepatol. 2020;73(2):441&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194911</ArticleId><ArticleId IdType="pubmed">32298769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Beatrice G., Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis, Liver international : official journal of the International Association for the Study of the. Liver. 2020;40(6):1316&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">32329563</ArticleId></ArticleIdList></Reference><Reference><Citation>Watt K.D. Keys to long-term care of the liver transplant recipient. Nat. Rev. Gastroenterol. Hepatol. 2015;12(11):639&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">26460351</ArticleId></ArticleIdList></Reference><Reference><Citation>Ben&#xed;tez C., Londo&#xf1;o M.C., Miquel R., Manzia T.M., Abraldes J.G., Lozano J.J., Mart&#xed;nez-Llordella M., L&#xf3;pez M., Angelico R., Bohne F., Sese P., Daoud F., Larcier P., Roelen D.L., Claas F., Whitehouse G., Lerut J., Pirenne J., Rimola A., Tisone G., S&#xe1;nchez-Fueyo A. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology (Baltimore, Md.) 2013;58(5):1824&#x2013;1835.</Citation><ArticleIdList><ArticleId IdType="pubmed">23532679</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmenero J., Rodr&#xed;guez-Per&#xe1;lvarez M., Salcedo M., Arias-Milla A., Mu&#xf1;oz-Serrano A., Graus J., Nu&#xf1;o J., Gastaca M., Bustamante-Schneider J., Cachero A., Llad&#xf3; L., Caballero A., Fern&#xe1;ndez-Yunquera A., Loinaz C., Fern&#xe1;ndez I., Fondevila C., Navasa M., I&#xf1;arrairaegui M., Castells L., Pascual S., Ram&#xed;rez P., Vinaixa C., Gonz&#xe1;lez-Dieguez M.L., Gonz&#xe1;lez-Grande R., Hierro L., Nogueras F., Otero A., &#xc1;lamo J.M., Blanco-Fern&#xe1;ndez G., F&#xe1;brega E., Garc&#xed;a-Pajares F., Montero J.L., Tom&#xe9; S., De la Rosa G., Pons J.A. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J. Hepatol. 2021;74(1):148&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7395653</ArticleId><ArticleId IdType="pubmed">32750442</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravanan R., Callaghan C.J., Mumford L., Ushiro-Lumb I., Thorburn D., Casey J., Friend P., Parameshwar J., Currie I., Burnapp L., Baker R., Dudley J., Oniscu G.C., Berman M., Asher J., Harvey D., Manara A., Manas D., Gardiner D., Forsythe J.L.R. SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2020;20(11):3008&#x2013;3018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436919</ArticleId><ArticleId IdType="pubmed">32780493</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb G.J., Marjot T., Cook J.A., Aloman C., Armstrong M.J., Brenner E.J., Catana M.A., Cargill T., Dhanasekaran R., Garc&#xed;a-Ju&#xe1;rez I., Hagstr&#xf6;m H., Kennedy J.M., Marshall A., Masson S., Mercer C.J., Perumalswami P.V., Ruiz I., Thaker S., Ufere N.N., Barnes E., Barritt A.S.t., Moon A.M. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol. Hepatol. 2020;5(11):1008&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455160</ArticleId><ArticleId IdType="pubmed">32866433</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauber C., Tiwari-Heckler S., Pfeiffenberger J., Mehrabi A., Lund F., Gath P., Mieth M., Merle U., Rupp C. SARS-CoV-2 seroprevalence and clinical features of COVID-19 in a German liver transplant recipient cohort: A prospective serosurvey study. Transpl. Proc. 2021;53(4):1112&#x2013;1117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831557</ArticleId><ArticleId IdType="pubmed">33451759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B.T., Perumalswami P.V., Im G.Y., Florman S., Schiano T.D. COVID-19 in liver transplant recipients: An initial experience from the US epicenter. Gastroenterology. 2020;159(3):1176&#x2013;1178.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7237372</ArticleId><ArticleId IdType="pubmed">32442561</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M.R., Mohan S., Cohen D.J., Husain S.A., Dube G.K., Ratner L.E., Arcasoy S., Aversa M.M., Benvenuto L.J., Dadhania D.M., Kapur S., Dove L.M., Brown R.S., Jr., Rosenblatt R.E., Samstein B., Uriel N., Farr M.A., Satlin M., Small C.B., Walsh T.J., Kodiyanplakkal R.P., Miko B.A., Aaron J.G., Tsapepas D.S., Emond J.C., Verna E.C. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2020;20(7):1800&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264777</ArticleId><ArticleId IdType="pubmed">32330343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur A.K., Schaubel D.E., Gong Q., Guidinger M.K., Merion R.M. Sex-based disparities in liver transplant rates in the United States. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2011;11(7):1435&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132137</ArticleId><ArticleId IdType="pubmed">21718440</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P., Schaubel D.E., Guidinger M.K., Goodrich N.P., Ojo A.O., Merion R.M. Impact of MELD-based allocation on end-stage renal disease after liver transplantation. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2011;11(11):2372&#x2013;2378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203341</ArticleId><ArticleId IdType="pubmed">21883908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber S.R., Lee R.A., Jiang Y., Reuter C., Watkins R., Szempruch K., Gerber D.A., Desai C.S., DeCherney G.S., Barritt A.S.T. The impact of post-transplant diabetes mellitus on liver transplant outcomes. Clin. Transplant. 2019;33(6):e13554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995642</ArticleId><ArticleId IdType="pubmed">30927288</ArticleId></ArticleIdList></Reference><Reference><Citation>Everhart J.E., Lombardero M., Lake J.R., Wiesner R.H., Zetterman R.K., Hoofnagle J.H. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transplant. Surg.: Off. Publicat. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 1998;4(4):285&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">9649642</ArticleId></ArticleIdList></Reference><Reference><Citation>Su F., Yu L., Berry K., Liou I.W., Landis C.S., Rayhill S.C., Reyes J.D., Ioannou G.N. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology. 2016;150(2):441&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">26522262</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyam M., Neuberger J.M., Gunson B.K., H&#xfc;bscher S.G. Cirrhosis after orthotopic liver transplantation in the absence of primary disease recurrence. Liver Transplant. Surg.: Off. Publicat. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2007;13(7):966&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">17370332</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabiee A., Sadowski B., Adeniji N., Perumalswami P.V., Nguyen V., Moghe A., Latt N.L., Kumar S., Aloman C., Catana A.M., Bloom P.P., Chavin K.D., Carr R.M., Dunn W., Chen V.L., Aby E.S., Debes J.D., Dhanasekaran R. Liver Injury in liver transplant recipients with coronavirus disease 2019 (COVID-19): U.S. multicenter experience. Hepatology (Baltimore Md.) 2020;72(6):1900&#x2013;1911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537191</ArticleId><ArticleId IdType="pubmed">32964510</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift A.K., Coupland C.A.C., Keogh R.H., Diaz-Ordaz K., Williamson E., Harrison E.M., Hayward A., Hemingway H., Horby P., Mehta N., Benger J., Khunti K., Spiegelhalter D., Sheikh A., Valabhji J., Lyons R.A., Robson J., Semple M.G., Kee F., Johnson P., Jebb S., Williams T., Hippisley-Cox J. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ (Clinical research ed.) 2020;371</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B., Lavin Y., Swartz T.H., Madduri D., Stock A., Marron T.U., Xie H., Patel M., Tuballes K., Van Oekelen O., Rahman A., Kovatch P., Aberg J.A., Schadt E., Jagannath S., Mazumdar M., Charney A.W., Firpo-Betancourt A., Mendu D.R., Jhang J., Reich D., Sigel K., Cordon-Cardo C., Feldmann M., Parekh S., Merad M., Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26(10):1636&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>Q. Zhang, P. Bastard, Z. Liu, J. Le Pen, M. Moncada-Velez, J. Chen, M. Ogishi, I.K.D. Sabli, S. Hodeib, C. Korol, J. Rosain, K. Bilguvar, J. Ye, A. Bolze, B. Bigio, R. Yang, A.A. Arias, Q. Zhou, Y. Zhang, F. Onodi, S. Korniotis, L. Karpf, Q. Philippot, M. Chbihi, L. Bonnet-Madin, K. Dorgham, N. Smith, W.M. Schneider, B.S. Razooky, H.H. Hoffmann, E. Michailidis, L. Moens, J.E. Han, L. Lorenzo, L. Bizien, P. Meade, A.L. Neehus, A.C. Ugurbil, A. Corneau, G. Kerner, P. Zhang, F. Rapaport, Y. Seeleuthner, J. Manry, C. Masson, Y. Schmitt, A. Schl&#xfc;ter, T. Le Voyer, T. Khan, J. Li, J. Fellay, L. Roussel, M. Shahrooei, M.F. Alosaimi, D. Mansouri, H. Al-Saud, F. Al-Mulla, F. Almourfi, S.Z. Al-Muhsen, F. Alsohime, S. Al Turki, R. Hasanato, D. van de Beek, A. Biondi, L.R. Bettini, M. D'Angio, P. Bonfanti, L. Imberti, A. Sottini, S. Paghera, E. Quiros-Roldan, C. Rossi, A.J. Oler, M.F. Tompkins, C. Alba, I. Vandernoot, J.C. Goffard, G. Smits, I. Migeotte, F. Haerynck, P. Soler-Palacin, A. Martin-Nalda, R. Colobran, P.E. Morange, S. Keles, F. &#xc7;&#xf6;lkesen, T. Ozcelik, K.K. Yasar, S. Senoglu, N. Karabela &#x15e;, C. Rodr&#xed;guez-Gallego, G. Novelli, S. Hraiech, Y. Tandjaoui-Lambiotte, X. Duval, C. Laou&#xe9;nan, A.L. Snow, C.L. Dalgard, J.D. Milner, D.C. Vinh, T.H. Mogensen, N. Marr, A.N. Spaan, B. Boisson, S. Boisson-Dupuis, J. Bustamante, A. Puel, M.J. Ciancanelli, I. Meyts, T. Maniatis, V. Soumelis, A. Amara, M. Nussenzweig, A. Garc&#xed;a-Sastre, F. Krammer, A. Pujol, D. Duffy, R.P. Lifton, S.Y. Zhang, G. Gorochov, V. B&#xe9;ziat, E. Jouanguy, V. Sancho-Shimizu, C.M. Rice, L. Abel, L.D. Notarangelo, A. Cobat, H.C. Su, J.L. Casanova, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science (New York, N.Y.) 370(6515) (2020) 1-14.</Citation></Reference><Reference><Citation>P. Bastard, L.B. Rosen, Q. Zhang, E. Michailidis, H.H. Hoffmann, Y. Zhang, K. Dorgham, Q. Philippot, J. Rosain, V. B&#xe9;ziat, J. Manry, E. Shaw, L. Haljasm&#xe4;gi, P. Peterson, L. Lorenzo, L. Bizien, S. Trouillet-Assant, K. Dobbs, A.A. de Jesus, A. Belot, A. Kallaste, E. Catherinot, Y. Tandjaoui-Lambiotte, J. Le Pen, G. Kerner, B. Bigio, Y. Seeleuthner, R. Yang, A. Bolze, A.N. Spaan, O.M. Delmonte, M.S. Abers, A. Aiuti, G. Casari, V. Lampasona, L. Piemonti, F. Ciceri, K. Bilguvar, R.P. Lifton, M. Vasse, D.M. Smadja, M. Migaud, J. Hadjadj, B. Terrier, D. Duffy, L. Quintana-Murci, D. van de Beek, L. Roussel, D.C. Vinh, S.G. Tangye, F. Haerynck, D. Dalmau, J. Martinez-Picado, P. Brodin, M.C. Nussenzweig, S. Boisson-Dupuis, C. Rodr&#xed;guez-Gallego, G. Vogt, T.H. Mogensen, A.J. Oler, J. Gu, P.D. Burbelo, J.I. Cohen, A. Biondi, L.R. Bettini, M. D'Angio, P. Bonfanti, P. Rossignol, J. Mayaux, F. Rieux-Laucat, E.S. Husebye, F. Fusco, M.V. Ursini, L. Imberti, A. Sottini, S. Paghera, E. Quiros-Roldan, C. Rossi, R. Castagnoli, D. Montagna, A. Licari, G.L. Marseglia, X. Duval, J. Ghosn, J.S. Tsang, R. Goldbach-Mansky, K. Kisand, M.S. Lionakis, A. Puel, S.Y. Zhang, S.M. Holland, G. Gorochov, E. Jouanguy, C.M. Rice, A. Cobat, L.D. Notarangelo, L. Abel, H.C. Su, J.L. Casanova, Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science (New York, N.Y.) 370(6515) (2020) 1-13.</Citation></Reference><Reference><Citation>Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S.N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384(8):693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Merli M., Perricone G., Lauterio A., Prosperi M., Travi G., Roselli E., Petr&#xf2; L., De Carlis L., Belli L., Puoti M. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Trans.: Off. Publicat. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2020;26(11):1543&#x2013;1544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300680</ArticleId><ArticleId IdType="pubmed">32475054</ArticleId></ArticleIdList></Reference><Reference><Citation>Monti S., Balduzzi S., Delvino P., Bellis E., Quadrelli V.S., Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann. Rheum. Dis. 2020;79(5):667&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211079</ArticleId><ArticleId IdType="pubmed">32241793</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A., Invernizzi P., Lohse A.W., Aghemo A., Carbone M. Management of patients with autoimmune liver disease during COVID-19 pandemic. J. Hepatol. 2020;73(2):453&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151539</ArticleId><ArticleId IdType="pubmed">32283134</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau G., Ward J.W. Synthesis of liver associations recommendations for hepatology and liver transplant care during the COVID-19 pandemic. Clin. Liver Dis. 2020;15(5):204&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242013</ArticleId><ArticleId IdType="pubmed">32489655</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K.R. SARS-CoV-2 and the Liver: Considerations in hepatitis B and hepatitis C infections. Clin. Liver Dis. 2020;15(5):191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242007</ArticleId><ArticleId IdType="pubmed">32489654</ArticleId></ArticleIdList></Reference><Reference><Citation>Zha L., Li S., Pan L., Tefsen B., Li Y., French N., Chen L., Yang G., Villanueva E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med. J. Aust. 2020;212(9):416&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262211</ArticleId><ArticleId IdType="pubmed">32266987</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco J.L., Ambrosioni J., Garcia F., Mart&#xed;nez E., Soriano A., Mallolas J., Miro J.M. COVID-19 in patients with HIV: clinical case series. The lancet. HIV. 2020;7(5):e314&#x2013;e316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159872</ArticleId><ArticleId IdType="pubmed">32304642</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Cao Y., Xu S., Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city China. J. Med. Virol. 2020;92(6):529&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228399</ArticleId><ArticleId IdType="pubmed">32160316</ArticleId></ArticleIdList></Reference><Reference><Citation>Altuntas Aydin O., Kumbasar Karaosmanoglu H., Kart Yasar K. HIV/SARS-CoV-2 coinfected patients in Istanbul, Turkey. J. Med. Virol. 2020;92(11):2288&#x2013;2290.</Citation><ArticleIdList><ArticleId IdType="pubmed">32347975</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Cheng X., Wang R., Zeng X. Computed tomography imaging of an HIV-infected patient with coronavirus disease 2019. J. Med. Virol. 2020;92(10):1774&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262132</ArticleId><ArticleId IdType="pubmed">32285949</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Liao X., Wang H., Wei L., Xing M., Liu L., Zhang Z. Early virus clearance and delayed antibody response in a case of coronavirus disease 2019 (COVID-19) with a history of coinfection with human immunodeficiency virus type 1 and hepatitis C virus. Clin. Infect. Dis. 2020;71(16):2233&#x2013;2235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184426</ArticleId><ArticleId IdType="pubmed">32270178</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhoudian A., Baldacchino A., Clark N., Gerra G., Ekhtiari H., Dom G., Mokri A., Sadeghi M., Nematollahi P., Demasi M., Sch&#xfc;tz C.G., Hash-Emian S.M., Tabarsi P., Galea-Singer S., Carr&#xe0; G., Clausen T., Kouimtsidis C., Tolomeo S., Radfar S.R., Razaghi E.M. COVID-19 and substance use disorders: Recommendations to a comprehensive healthcare response. Int. Soc. Addict. Med. Pract. Policy Interest Group Position Paper, Basic and Clin. Neurosci. 2020;11(2):133&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7368103</ArticleId><ArticleId IdType="pubmed">32855772</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K.R., Beavers K.L., Hammond S.P., Lim J.K., Falck-Ytter Y.T. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215&#x2013;219. quiz e16-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25447850</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.F., Mo Y.Q., Jing J., Ma J.D., Zheng D.H., Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int. J. Rheum. Dis. 2017;20(7):859&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">28160426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alqahtani S.A., Aljumah A.A., Hashim A., Alenazi T.H., AlJawad M., Al Hamoudi W.K., Alghamdi M.Y. Principles of care for patients with liver disease during the coronavirus disease 2019 (COVID-19) pandemic: Position statement of the saudi association for the study of liver disease and transplantation. Ann. Saudi Med. 2020;40(4):273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316371</ArticleId><ArticleId IdType="pubmed">32564624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblatt R., Verna E.C. COVID 19: Management of decompensated cirrhosis and liver transplant recipients. Clin. Liver Dis. 2020;15(5):200&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280636</ArticleId><ArticleId IdType="pubmed">32537136</ArticleId></ArticleIdList></Reference><Reference><Citation>Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F.X., Chong M., Lee M. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington state. JAMA. 2020;323(16):1612&#x2013;1614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7082763</ArticleId><ArticleId IdType="pubmed">32191259</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg I.S., Jacobson I.M. Cardiovascular diseases and the liver. Clin. Liver Dis. 2011;15(1):1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21111990</ArticleId></ArticleIdList></Reference><Reference><Citation>van Deursen V.M., Damman K., Hillege H.L., van Beek A.P., van Veldhuisen D.J., Voors A.A. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J. Card. Fail. 2010;16(1):84&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">20123323</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper E.B., Sengupta N., Bonder A. the incidence and outcomes of ischemic hepatitis: A systematic review with meta-analysis. Am. J. Med. 2015;128(12):1314&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pubmed">26299319</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Fuchs, A.J. Sanyal, Sepsis and cholestasis, Clinics in liver disease 12(1) (2008) 151-72, ix.</Citation><ArticleIdList><ArticleId IdType="pubmed">18242502</ArticleId></ArticleIdList></Reference><Reference><Citation>Grein J., Ohmagari N., Shin D., Diaz G., Asperges E., Castagna A., Feldt T., Green G., Green M.L., Lescure F.X., Nicastri E., Oda R., Yo K., Quiros-Roldan E., Studemeister A., Redinski J., Ahmed S., Bernett J., Chelliah D., Chen D., Chihara S., Cohen S.H., Cunningham J., D'Arminio Monforte A., Ismail S., Kato H., Lapadula G., L'Her E., Maeno T., Majumder S., Massari M., Mora-Rillo M., Mutoh Y., Nguyen D., Verweij E., Zoufaly A., Osinusi A.O., DeZure A., Zhao Y., Zhong L., Chokkalingam A., Elboudwarej E., Telep L., Timbs L., Henne I., Sellers S., Cao H., Tan S.K., Winterbourne L., Desai P., Mera R., Gaggar A., Myers R.P., Brainard D.M., Childs R., Flanigan T. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020;382(24):2327&#x2013;2336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169476</ArticleId><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.Q., Wan X.D., Zhu S., Han H.M., Xu Z.S., Lu H.J. Establishment of a new animal model of azithromycin-induced liver injury and study the molecular pathological change during the process. Hum. Exp. Toxicol. 2016;35(5):511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">26205530</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh R.F., Gaver V.E., Patterson K.B., Rezk N.L., Baxter-Meheux F., Blake M.J., Eron J.J., Jr., Klein C.E., Rublein J.C., Kashuba A.D. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquired Immune Deficiency Syndr. (1999) 2006;42(1):52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">16639344</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel Galil S.M. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus. 2015;24(6):638&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">25424894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao Y., Wang P., Shao X., Zhu J., Xiao J., Shi J., Zhang L., Zhu H.J., Ma X., Manautou J.E., Zhong X.B. Acetaminophen-induced liver injury alters expression and activities of cytochrome P450 enzymes in an age-dependent manner in mouse liver. Drug Metab. Dispos. 2020;48(5):326&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153563</ArticleId><ArticleId IdType="pubmed">32094214</ArticleId></ArticleIdList></Reference><Reference><Citation>Makin A.J., Wendon J., Fitt S., Portmann B.C., Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35(4):569&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1374814</ArticleId><ArticleId IdType="pubmed">8175002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H., Li Y., Hu Z., Zhong W., Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery. 2020;6:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078228</ArticleId><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez M.A., Vuppalanchi R., Fontana R.J., Stolz A., Kleiner D.E., Hayashi P.H., Gu J., Hoofnagle J.H., Chalasani N. Clinical and histologic features of azithromycin-induced liver injury. Clin. Gastroenterol. Hepatol.: Off. Clin.Pract. J. Am. Gastroenterol. Assoc. 2015;13(2):369&#x2013;376.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321982</ArticleId><ArticleId IdType="pubmed">25111234</ArticleId></ArticleIdList></Reference><Reference><Citation>G.A. FitzGerald, Misguided drug advice for COVID-19, Science (New York, N.Y.) 367(6485) (2020) 1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">32198292</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng S.Q., Peng H.J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J. Clin. Med. 2020;9(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7074453</ArticleId><ArticleId IdType="pubmed">32093211</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao B., Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: Friend or foe? Gastroenterology. 2016;150(8):1704&#x2013;1709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887345</ArticleId><ArticleId IdType="pubmed">26826669</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Jr., Hammitt L.L., T&#xfc;reci &#xd6;., Nell H., Schaefer A., &#xdc;nal S., Tresnan D.B., Mather S., Dormitzer P.R., &#x15e;ahin U., Jansen K.U., Gruber W.C. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383(27):2603&#x2013;2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., Bibi S., Briner C., Cicconi P., Collins A.M., Colin-Jones R., Cutland C.L., Darton T.C., Dheda K., Duncan C.J.A., Emary K.R.W., Ewer K.J., Fairlie L., Faust S.N., Feng S., Ferreira D.M., Finn A., Goodman A.L., Green C.M., Green C.A., Heath P.T., Hill C., Hill H., Hirsch I., Hodgson S.H.C., Izu A., Jackson S., Jenkin D., Joe C.C.D., Kerridge S., Koen A., Kwatra G., Lazarus R., Lawrie A.M., Lelliott A., Libri V., Lillie P.J., Mallory R., Mendes A.V.A., Milan E.P., Minassian A.M., McGregor A., Morrison H., Mujadidi Y.F., Nana A., O'Reilly P.J., Padayachee S.D., Pittella A., Plested E., Pollock K.M., Ramasamy M.N., Rhead S., Schwarzbold A.V., Singh N., Smith A., Song R., Snape M.D., Sprinz E., Sutherland R.K., Tarrant R., Thomson E.C., T&#xf6;r&#xf6;k M.E., Toshner M., Turner D.P.J., Vekemans J., Villafana T.L., Watson M.E.E., Williams C.J., Douglas A.D., Hill A.V.S., Lambe T., Gilbert S.C., Pollard A.J. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England) 2021;397(10269):99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., McGettigan J., Khetan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B.S., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., Zaks T. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384(5):403&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet (London, England) 2021;397(10275):671&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Webb G.J., Barritt A.S., Gin&#xe8;s P., Lohse A.W., Moon A.M., Pose E., Trivedi P., Barnes E. SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol. Hepatol. 2021;6(3):156&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832019</ArticleId><ArticleId IdType="pubmed">33444545</ArticleId></ArticleIdList></Reference><Reference><Citation>Leboss&#xe9; F., Gudd C., Tunc E., Singanayagam A., Nathwani R., Triantafyllou E., Pop O., Kumar N., Mukherjee S., Hou T.Z., Quaglia A., Zoulim F., Wendon J., Dhar A., Thursz M., Antoniades C.G., Khamri W. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine. 2019;49:258&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6945243</ArticleId><ArticleId IdType="pubmed">31678004</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaskou E., Hirschfield G.M. Cirrhosis-associated immune dysfunction: Novel insights in impaired adaptive immunity. EBioMedicine. 2019;50:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6921234</ArticleId><ArticleId IdType="pubmed">31727600</ArticleId></ArticleIdList></Reference><Reference><Citation>McCashland T.M., Preheim L.C., Gentry M.J. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis. 2000;181(2):757&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">10669371</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggeletopoulou I., Davoulou P., Konstantakis C., Thomopoulos K., Triantos C. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev. Med. Virol. 2017;27(6)</Citation><ArticleIdList><ArticleId IdType="pubmed">28905444</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P.P., Avery R.K. A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients. Clin. Ther. 2017;39(8):1581&#x2013;1598.</Citation><ArticleIdList><ArticleId IdType="pubmed">28751095</ArticleId></ArticleIdList></Reference><Reference><Citation>G. Garcia-Tsao, J.G. Abraldes, A. Berzigotti, J. Bosch, Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases, Hepatology (Baltimore, Md.) 65(1) (2017) 310-335.</Citation><ArticleIdList><ArticleId IdType="pubmed">27786365</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Moon A.M., Cook J.A., Abd-Elsalam S., Aloman C., Armstrong M.J., Pose E., Brenner E.J., Cargill T., Catana M.A., Dhanasekaran R., Eshraghian A., Garc&#xed;a-Ju&#xe1;rez I., Gill U.S., Jones P.D., Kennedy J., Marshall A., Matthews C., Mells G., Mercer C., Perumalswami P.V., Avitabile E., Qi X., Su F., Ufere N.N., Wong Y.J., Zheng M.H., Barnes E., Barritt A.S.t., Webb G.J. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J. Hepatol. 2021;74(3):567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536538</ArticleId><ArticleId IdType="pubmed">33035628</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T., Buescher G., Sebode M., Barnes E., Barritt A.S.t., Armstrong M.J., Baldelli L., Kennedy J., Mercer C., Ozga A.K., Casar C., Schramm C., Moon A.M., Webb G.J., Lohse A.W. SARS-CoV-2 infection in patients with autoimmune hepatitis. J. Hepatol. 2021;74(6):1335&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7835076</ArticleId><ArticleId IdType="pubmed">33508378</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolis A.S., Manolis T.A., Manolis A.A., Papatheou D., Melita H. COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management. J. Cardiovasc. Pharmacol. Ther. 2021;26(1):12&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492826</ArticleId><ArticleId IdType="pubmed">32924567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Nigoghossian C., Ageno W., Madjid M., Guo Y., Tang L.V., Hu Y., Giri J., Cushman M., Qu&#xe9;r&#xe9; I., Dimakakos E.P., Gibson C.M., Lippi G., Favaloro E.J., Fareed J., Caprini J.A., Tafur A.J., Burton J.R., Francese D.P., Wang E.Y., Falanga A., McLintock C., Hunt B.J., Spyropoulos A.C., Barnes G.D., Eikelboom J.W., Weinberg I., Schulman S., Carrier M., Piazza G., Beckman J.A., Steg P.G., Stone G.W., Rosenkranz S., Goldhaber S.Z., Parikh S.A., Monreal M., Krumholz H.M., Konstantinides S.V., Weitz J.I., Lip G.Y.H. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020;75(23):2950&#x2013;2973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffredo L., Pastori D., Farcomeni A., Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;153(2):480&#x2013;487.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28479379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tritschler T., Mathieu M.E., Skeith L., Rodger M., Middeldorp S., Brighton T., Sandset P.M., Kahn S.R., Angus D.C., Blondon M., Bonten M.J., Cattaneo M., Cushman M., Derde L.P.G., DeSancho M.T., Diehl J.L., Goligher E., Jilma B., J&#xfc;ni P., Lawler P.R., Marietta M., Marshall J.C., McArthur C., Miranda C.H., Mirault T., Morici N., Perepu U., Sch&#xf6;rgenhofer C., Sholzberg M., Spyropoulos A.C., Webb S.A., Zarychanski R., Zuily S., Le Gal G. Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. Journal of thrombosis and haemostasis : JTH. 2020;18(11):2958&#x2013;2967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906402</ArticleId><ArticleId IdType="pubmed">32888372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemos A.C.B., do Esp&#xed;rito Santo D.A., Salvetti M.C., Gilio R.N., Agra L.B., Pazin-Filho A., Miranda C.H. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID) Thromb. Res. 2020;196:359&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7503069</ArticleId><ArticleId IdType="pubmed">32977137</ArticleId></ArticleIdList></Reference><Reference><Citation>Erman A., Wong W.W.L., Feld J.J., Grootendorst P., Krahn M.D. The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. Liver Int.: Off. J. Int. Assoc. Study Liver. 2020;40(1):51&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">31509639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Hsu Y.C., Ho H.J., Chen Y.J., Lee T.Y., Lin J.T. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65(4):693&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pubmed">25670811</ArticleId></ArticleIdList></Reference><Reference><Citation>Amaddeo G., Brustia R., Allaire M., Lequoy M., Hollande C., Regnault H., Blaise L., Ganne-Carri&#xe9; N., S&#xe9;ror O., Larrey E., Lim C., Scatton O., El Mouhadi S., Ozenne V., Paye F., Balladur P., Dohan A., Massault P.P., Pol S., Dioguardi Burgio M., Vilgrain V., Sepulveda A., Cauchy F., Luciani A., Sommacale D., Leroy V., Roudot-Thoraval F., Bouattour M., Nault J.C. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area. JHEP Rep.: Innovat. Hepatol. 2021;3(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604130</ArticleId><ArticleId IdType="pubmed">33163949</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maira T., Berenguer M. COVID-19 and liver transplantation. Nat. Rev. Gastroenterol. Hepatol. 2020;17(9):526&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351540</ArticleId><ArticleId IdType="pubmed">32651555</ArticleId></ArticleIdList></Reference><Reference><Citation>Merola J., Schilsky M.L., Mulligan D.C. The Impact of COVID-19 on Organ Donation, Procurement, and Liver Transplantation in the United States. Hepatol. Commun. 2021;5(1):5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537114</ArticleId><ArticleId IdType="pubmed">33043228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritschl P.V., Nevermann N., Wiering L., Wu H.H., Moroder P., Brandl A., Hillebrandt K., Tacke F., Friedersdorff F., Schlomm T., Sch&#xf6;ning W., &#xd6;llinger R., Schmelzle M., Pratschke J. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: A By-proxy Society Recommendation Consensus approach. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2020;20(7):1826&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264649</ArticleId><ArticleId IdType="pubmed">32323460</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorburn D., Taylor R., Whitney J., Adair A., Attia M., Gibbs P., Grammatikopoulos T., Isaac J.R., Masson S., Marshall A., Mirza D.F., Prachalias A., Watson S., Manas D.M., Forsythe J. Resuming liver transplantation amid the COVID-19 pandemic. Lancet Gastroenterol. Hepatol. 2021;6(1):12&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833625</ArticleId><ArticleId IdType="pubmed">33308431</ArticleId></ArticleIdList></Reference><Reference><Citation>E.C. Verna, M. Serper, J. Chu, K. Corey, O.K. Fix, K. Hoyt, K.A. Page, R. Loomba, M. Li, G.T. Everson, M.W. Fried, G. Garcia-Tsao, N. Terrault, A.S. Lok, R.T. Chung, K.R. Reddy, Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation, Hepatology (Baltimore, Md.) 72(5) (2020) 1819-1837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435542</ArticleId><ArticleId IdType="pubmed">32740969</ArticleId></ArticleIdList></Reference><Reference><Citation>I. Shahid A.R. Alzahrani S.S. Al-Ghamdi I.M. Alanazi S. Rehman S. Hassan Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises, Diagnostics 11 2021 (Basel, Switzerland).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8305142</ArticleId><ArticleId IdType="pubmed">34359335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicola M., Alsafi Z., Sohrabi C., Kerwan A., Al-Jabir A., Iosifidis C., Agha M., Agha R. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int. J. Surgery (London, England) 2020;78:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7162753</ArticleId><ArticleId IdType="pubmed">32305533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassisi M., Audo I., Zeitz C., Varin J., Wohlschlegel J., Smirnov V., Santiard-Baron D., Picaud S., Sahel J.A. Impact of the COVID-19 lockdown on basic science research in ophthalmology: the experience of a highly specialized research facility in France. Eye (Lond.) 2020;34(7):1187&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205025</ArticleId><ArticleId IdType="pubmed">32382143</ArticleId></ArticleIdList></Reference><Reference><Citation>Blach S., Kondili L.A., Aghemo A., Cai Z., Dugan E., Estes C., Gamkrelidze I., Ma S., Pawlotsky J.M., Razavi-Shearer D., Razavi H., Waked I., Zeuzem S., Craxi A. Impact of COVID-19 on global HCV elimination efforts. J. Hepatol. 2021;74(1):31&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7411379</ArticleId><ArticleId IdType="pubmed">32777322</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology T.L.G. Eliminating viral hepatitis in the COVID-19 era: weighing challenge and opportunity. Lancet Gastroenterol. Hepatol. 2020;5(9):789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7384776</ArticleId><ArticleId IdType="pubmed">32730787</ArticleId></ArticleIdList></Reference><Reference><Citation>Serper M., Shaked A., Olthoff K.M., Hoteit M., Appolo B., Reddy K.R. A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities. J. Hepatol. 2020;73(3):708&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7242929</ArticleId><ArticleId IdType="pubmed">32450089</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzwiedz C.L., Green M.J., Benzeval M., Campbell D., Craig P., Demou E., Leyland A., Pearce A., Thomson R., Whitley E., Katikireddi S.V. Mental health and health behaviours before and during the initial phase of the COVID-19 lockdown: longitudinal analyses of the UK Household Longitudinal Study. J. Epidemiol. Community Health. 2021;75(3):224&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7892383</ArticleId><ArticleId IdType="pubmed">32978210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.U., Majid A., Judge R., Crook P., Nathwani R., Selvapatt N., Lovendoski J., Manousou P., Thursz M., Dhar A., Lewis H., Vergis N., Lemoine M. Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder. Lancet Gastroenterol. Hepatol. 2020;5(10):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403133</ArticleId><ArticleId IdType="pubmed">32763197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cargill Z., Kattiparambil S., Hansi N., Barnabas A., Shawcross D.L., Williams R., Agarwal K. Severe alcohol-related liver disease admissions post-COVID-19 lockdown: canary in the coal mine? Frontline Gastroenterol. 2021;12(4):354&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8231423</ArticleId><ArticleId IdType="pubmed">34249324</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini M., Ponzo V., Rosato R., Scumaci E., Goitre I., Benso A., Belcastro S., Crespi C., De Michieli F., Ghigo E., Broglio F., Bo S. Changes in weight and nutritional habits in adults with obesity during the &#x201c;lockdown&#x201d; period caused by the COVID-19 virus emergency. Nutrients. 2020;12(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7400808</ArticleId><ArticleId IdType="pubmed">32645970</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmud N., Hubbard R.A., Kaplan D.E., Serper M. Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study. Gastroenterology. 2020;159(3):1134&#x2013;1136.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200325</ArticleId><ArticleId IdType="pubmed">32387493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Lv F., He X., Zhao Y., Liu Y., Zu J., Henry L., Wang J., Yeo Y.H., Ji F., Nguyen M.H. Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States. J. Hepatol. 2022;78(1):16&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9611810</ArticleId><ArticleId IdType="pubmed">35988691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.R., Kang M.K., Song J.E., Kim H.J., Kweon Y.O., Tak W.Y., Jang S.Y., Park J.G., Lee C., Hwang J.S., Jang B.K., Suh J.I., Chung W.J., Kim B.S., Park S.Y. Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea. Clin. Mol. Hepatol. 2020;26(4):562&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641571</ArticleId><ArticleId IdType="pubmed">33053932</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xe1;zquez-Medina M.U., Cerda-Reyes E., Galeana-Pav&#xf3;n A., L&#xf3;pez-Luna C.E., Ram&#xed;rez-Portillo P.M., Iba&#xf1;ez-Cervantes G., Torres-V&#xe1;zquez J., Vargas-De-Le&#xf3;n C. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019. Hepatol. Commun. 2022;6(8):2000&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110946</ArticleId><ArticleId IdType="pubmed">35438253</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao J., Liang Y., Li Y., Ding R., Zhu M., You W., Wang Z., Huang B., Wu M., Zhang T., Li K., Wu W., Wu L., Wang Q., Xia X., Wang S., Lu L. Implications of liver injury in risk-stratification and management of patients with COVID-19. Hep. Intl. 2021;15(1):202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865118</ArticleId><ArticleId IdType="pubmed">33548030</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S., Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: A multicenter research network study. Gastroenterology. 2020;159(2):768&#x2013;771.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196546</ArticleId><ArticleId IdType="pubmed">32376408</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon A.M., Webb G.J., Aloman C., Armstrong M.J., Cargill T., Dhanasekaran R., Genesc&#xe0; J., Gill U.S., James T.W., Jones P.D., Marshall A., Mells G., Perumalswami P.V., Qi X., Su F., Ufere N.N., Barnes E., Barritt A.S., Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J. Hepatol. 2020;73(3):705&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241346</ArticleId><ArticleId IdType="pubmed">32446714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J., Pletcher M.J., Lai J.C. Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: A national COVID cohort collaborative study. Gastroenterology. 2021;161(5):1487&#x2013;1501.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286237</ArticleId><ArticleId IdType="pubmed">34284037</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhoori S., Rossi R.E., Citterio D., Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol. Hepatol. 2020;5(6):532&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146678</ArticleId><ArticleId IdType="pubmed">32278366</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar M.Z., Bhalla A., Azhar A., Tsujita M., Talwar M., Balaraman V., Sodhi A., Kadaria D., Eason J.D., Hayek S.S., Coca S.G., Shaefi S., Neyra J.A., Gupta S., Leaf D.E., Kovesdy C.P. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transplant Surg. 2020;20(11):3061&#x2013;3071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460925</ArticleId><ArticleId IdType="pubmed">32844546</ArticleId></ArticleIdList></Reference><Reference><Citation>Polak W.G., Fondevila C., Karam V., Adam R., Baumann U., Germani G., Nadalin S., Taimr P., Toso C., Troisi R.I., Zieniewicz K., Belli L.S., Duvoux C. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European liver and intestine transplantation association and European liver transplant registry. Transplant Int. Off. J. Euro. Soc. Organ Transplant. 2020;33(10):1244&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361228</ArticleId><ArticleId IdType="pubmed">32609908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Chen C., Tang J., Wang C., Zhou M., Cheng Y., Zhou X., Wu Q., Zhang X., Feng Z., Wang M., Mao Q. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann. Med. 2022;54(1):516&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19/, 2021 (accessed 5 May 2023).</Citation></Reference><Reference><Citation>Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults; https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19/, 2021 (accessed 6 May 2023).</Citation></Reference><Reference><Citation>Molnupiravir. 2022 https://www.ncbi.nlm.nih.gov/books/NBK577814/ accessed 7 May 2023.</Citation></Reference><Reference><Citation>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Paxlovid. https://www.ncbi.nlm.nih.gov/books/NBK577815/, 2022 (accessed 8 May 2023).</Citation></Reference><Reference><Citation>Medhat M.A., El-Kassas M., Karam-Allah H., Al Shafie A., Abd-Elsalam S., Moustafa E., Hassany S.M., Salama M., Abd Elghafar M.S., Sayed H., Badr M., Kamal D.T., Shamseldeen A., Ossimi A., Moaz I., Esmael H.E., Ezz Eldin A.M., Ezzat S., Abdelghaffar H., Abdelghaffar K. Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals. Arab J. Gastroenterol.: Off. Publicat. Pan-Arab Assoc. Gastroenterol. 2022;23(3):165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116423</ArticleId><ArticleId IdType="pubmed">35690556</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamed M., El-Hasab M., Mansour F.R. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors. Virusdisease. 2021;32(2):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083918</ArticleId><ArticleId IdType="pubmed">33948452</ArticleId></ArticleIdList></Reference><Reference><Citation>The Pitfalls and Promise of Using Repurposed Drugs for COVID-19 https://www.medscape.com/viewarticle/952037/, 2021 (accessed 10 May 2023).</Citation></Reference><Reference><Citation>Hepatitis C Antivirals May Fight SARS-CoV-2; https://www.medscape.com/viewarticle/953902/, 2021 (accessed 11 May 2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>